The treatment of AR-positive prostate cancer cells with AU-15330 reduced DNA accessibility at oncogenic enhancer elements and disrupted enhancer–promoter loops and AR and FOXA1 occupancy, thereby suppressing oncogenic gene expression. Here, AR is linked to prostate carcinoma.